



350 - 4243 Glanford Ave.
Victoria, BC Canada V8Z 4B9
Tel: (250) 744-2811 Fax: (250) 744-2877
<http://www.stressgen.com>

00/05

Contact:

David Matthews
StressGen Biotechnologies
(250) 744-2811

Gretchen L. P. Schweitzer OR
Feinstein Kean Healthcare
(617) 577-8110

Fran DeVellis
Feinstein Kean Healthcare
(617) 577-8110

FOR IMMEDIATE RELEASE

StressGen to Present at 2nd Annual BIO CEO & Investor Conference

New York, NY, February 16, 2000 – Richard Glickman, President and Chief Executive Officer of StressGen Biotechnologies Corp. (TSE:SSB) will provide an update on StressGen’s stress protein technology and clinical development programs at the 2nd Annual BIO CEO & Investor Conference, the Company announced today. The presentation will be part of a panel, titled “Emerging Concepts in Immunotherapy,” to be held from 8:00 a.m. – 9:30 a.m. in the Astor Room at the Waldorf=Astoria Hotel in New York City.

StressGen is advancing a portfolio of therapeutic and vaccine products based on stress proteins, an important class of natural molecules that play a critical role in the activation and control of the immune system. StressGen’s lead product, HspE7, is comprised of the stress protein Hsp65 from *M. Bovis* BCG and the protein E7 from human papillomavirus (HPV), which is involved in the malignant transformation of anal and cervical epithelial cells. HspE7 is designed to direct a precise immune system attack on abnormal cells, offering a powerful, non-surgical approach to treat cervical and anal dysplasia.

In December 1999, StressGen announced positive results of a Phase I study of HspE7 in healthy volunteers and the initiation of an open label, multi-dose Phase II study in women with high-grade cervical dysplasia (CIN II/III). StressGen also recently initiated a Phase II study of HspE7 in immunocompetent male and female patients with anal dysplasia, and a Phase II trial in collaboration with the National Cancer Institute in HIV-positive patients with anal dysplasia.

StressGen Biotechnologies Corp. is a biopharmaceutical company developing innovative immunotherapy products to treat cancer and prevent infectious disease. Through its Biochemical Division, StressGen is also an internationally recognized supplier of stress protein, apoptosis, cell proliferation, protein phosphorylation, receptors and neuroscience research products.

The matters contained in this news release including, but not limited to clinical trials, regulatory matters, beliefs, and expectations are forward-looking statements. StressGen undertakes no obligation to publicly release the results of any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.